Professor of neurodegeneration; deputy director, Centre for Discovery Brain Sciences, University of Edinburgh
A body of studies is showing that a blood marker called p-tau217 can forecast an elevated risk of cognitive impairment in healthy older adults years before symptoms appear. The evidence is not yet clinical-ready, but it is guiding trials that aim to slow or prevent Alzheimer’s disease and is being tested in Scotland’s primary care setting.
Scotland is piloting BriDGe, a project using p-tau blood tests in over 50 GP practices to speed Alzheimer’s diagnosis, with up to 500 patients referred. Experts say this could shift dementia care toward earlier intervention with better access to treatment and support.